MabSwitch

Executive Summary

MabSwitch Inc. is a privately held biotechnology company founded in 2016 and headquartered in San Francisco, California. The company is pioneering the development of regulatable antibodies through its proprietary UNASMA™ platform, which enables external control of antibody binding affinity. This technology aims to enhance safety and efficacy in therapeutic, diagnostic, and bioprocessing applications by reducing on-target, off-tumor toxicity and allowing dynamic modulation of antibody activity. MabSwitch is currently in the preclinical stage, focusing on validating its platform across multiple targets. Given its novel approach to antibody regulation, the company has the potential to address key limitations of conventional antibody therapies. The technology's versatility could lead to partnerships with pharmaceutical companies seeking safer, more controllable biologics. However, as a private early-stage firm with limited public information, execution risks remain. The next 12-24 months will be critical for demonstrating platform proof-of-concept and securing additional funding or collaborations.

Upcoming Catalysts (preview)

• TBDPreclinical proof-of-concept data for lead candidate60% success
• TBDSeries A or B financing round completion70% success
• TBDStrategic partnership or licensing deal with major pharma40% success